insulin aspart vs Insulin lispro (Lyumjev)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: Insulin receptor · full Type 2 Diabetes pipeline

insulin aspart · NovoLog

Marketed by Novo Nordisk

Approved in Type 2 Diabetespeptide
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: June 2028 · NCT07652528 (registry estimate)

No aligned efficacy figure on record for this race.

Insulin lispro (Lyumjev)

Marketed by Eli Lilly

Approved in Type 2 Diabetespeptide
Partial signal

NCT03214380 · Phase 3 · completed

The study randomized and double-blinded participants to LY900014 or insulin lispro, with 933 enrolled and approximately 336-337 participants in the main comparison arms. The primary HbA1c endpoint met the prespecified non-inferiority margin, but HbA1c is a laboratory surrogate rather than a hard clinical endpoint, supporting a moderate evidence grade.

Reported efficacy

Change From Baseline in Hemoglobin A1c (HbA1c) (Baseline, Week 26): Change From Baseline in Hemoglobin A1c (HbA1c) (Baseline, Week 26): LY900014 -0.56 Percentage of HbA1c (Standard Error 0.046) vs Insulin Lispro (Humalog) -0.63 Percentage of HbA1c (Standard Error 0.061) (met)

Result source: NCT03952143

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointinsulin aspartInsulin lispro (Lyumjev)
HbA1c, change-1.2% vs -1.2%vs Insulin Glarginewk 26 · n 291NCT04880850
19 other results
  • -1.5% vs -1.4% BID · wk 26 · n 359 · Phase 3 · primary NCT02762578
  • -1.9% vs -1.7% wk 26 · n 197 · Phase 3 · primary NCT01513590
  • -1.4% vs -1.4% BID · wk 26 · n 280 · Phase 3 · primary NCT01059812
  • -1.6% vs -1.7% wk 26 · n 266 · Phase 3 · primary NCT01045707
  • -1.2% vs -1.3% once daily · wk 52 · n 744 · Phase 3 · primary NCT00972283
  • -0.7% vs 0.1% wk 26 · n 88 · Phase 3 · primary NCT01388361
  • -1.4% vs -1.2% OD · wk 26 · n 147 · Phase 3 · primary NCT01272193
  • -1.0% vs -1% once daily · wk 26 · n 230 · Phase 3 · primary NCT01045447
  • -1.3% vs -1.3% wk 26 · n 224 · Phase 3 · primary NCT01009580
  • -1.1% vs -1.1% twice daily · wk 4.14 · n 121 · Phase 3 · primary NCT02648217
  • -1.4% vs -1.3% wk 53 · n 266 · Phase 3 · secondary NCT01045707
  • -0.9% vs -1.1% once daily · wk 78 · n 744 · Phase 3 · secondary NCT00972283
  • -1.2% vs -1.3% wk 32 · n 164 · Phase 4 · primary NCT02453685
  • -1.0% vs -1.1% wk 32 · n 195 · Phase 4 · primary NCT01165684
  • -0.5% vs 0% once weekly · wk 26 · n 40 · Phase 4 · primary NCT04538352
  • 4.1% vs 3.4% wk 26 · n 46 · Phase 4 · primary NCT01966978
  • -0.5% vs -0.5% n 115 · Phase 2 · primary NCT01194258
  • -0.8% vs -1.1% wk 21 · n 195 · Phase 4 · secondary NCT01165684
  • -0.5% vs -1% wk 10 · n 193 · Phase 4 · secondary NCT01165684
-0.4% vs -0.4%vs Insulin Lispro (Humalog)wk 26 · n 334NCT03214380
1 other result
  • -0.6% vs -0.6% wk 26 · n 388 · Phase 3 · primary NCT03952143
Body weight, change (kg)2.7 vs 2.2vs Insulin Glarginewk 26 · n 291NCT04880850
11 other results
  • 2.8 vs 2.2 BID · wk 26 · n 359 · Phase 3 · secondary NCT02762578
  • 2.8 vs 2 wk 26 · n 196 · Phase 3 · secondary NCT01513590
  • -1 vs 0.1 wk 26 · n 87 · Phase 3 · secondary NCT01388361
  • 0.7 vs 0.7 OD · wk 26 · n 147 · Phase 3 · secondary NCT01272193
  • 1.1 vs 1.4 BID · wk 26 · n 279 · Phase 3 · secondary NCT01059812
  • 0.9 vs 0.3 wk 16 · n 117 · Phase 3 · secondary NCT01474538
  • -8.6 vs 1.4 once weekly · wk 26 · n 40 · Phase 4 · secondary NCT04538352
  • -0.6 vs 3.1 wk 26 · n 46 · Phase 4 · secondary NCT01966978
  • 1.5 vs 1.6 n 115 · Phase 2 · secondary NCT01194258
  • 0.3 vs 0.8 wk 26 · n 22 · Phase 4 · secondary NCT00998335
  • 0.1 vs -0.1 wk 6 · n 33 · Phase 2 · secondary NCT00842361
—Not reported
HbA1c below 7%44% vs 20%vs Metformin, Insulin Detemir, Insulin Aspartwk 26 · n 46NCT01966978—Not reported
Fasting plasma glucose, change-1.8 vs -1.6vs Insulin Glarginewk 26 · n 283NCT04880850
5 other results
  • -3.0 vs -1.6 BID · wk 26 · n 354 · Phase 3 · secondary NCT02762578
  • -4.4 vs -3.0 wk 26 · n 195 · Phase 3 · secondary NCT01513590
  • -0.1 vs -1.2 wk 26 · n 86 · Phase 3 · secondary NCT01388361
  • -2 vs -4.4 twice daily · wk 4.14 · n 115 · Phase 3 · secondary NCT02648217
  • 6.4 vs 4.9 wk 26 · n 22 · Phase 4 · secondary NCT00998335
—Not reported
3-point MACE (% with event)—Not posted · NCT01467323—Not reported

HbA1c, change

insulin aspart
-1.2% vs -1.2%vs Insulin Glarginewk 26 · n 291NCT04880850
19 other results
  • -1.5% vs -1.4% BID · wk 26 · n 359 · Phase 3 · primary NCT02762578
  • -1.9% vs -1.7% wk 26 · n 197 · Phase 3 · primary NCT01513590
  • -1.4% vs -1.4% BID · wk 26 · n 280 · Phase 3 · primary NCT01059812
  • -1.6% vs -1.7% wk 26 · n 266 · Phase 3 · primary NCT01045707
  • -1.2% vs -1.3% once daily · wk 52 · n 744 · Phase 3 · primary NCT00972283
  • -0.7% vs 0.1% wk 26 · n 88 · Phase 3 · primary NCT01388361
  • -1.4% vs -1.2% OD · wk 26 · n 147 · Phase 3 · primary NCT01272193
  • -1.0% vs -1% once daily · wk 26 · n 230 · Phase 3 · primary NCT01045447
  • -1.3% vs -1.3% wk 26 · n 224 · Phase 3 · primary NCT01009580
  • -1.1% vs -1.1% twice daily · wk 4.14 · n 121 · Phase 3 · primary NCT02648217
  • -1.4% vs -1.3% wk 53 · n 266 · Phase 3 · secondary NCT01045707
  • -0.9% vs -1.1% once daily · wk 78 · n 744 · Phase 3 · secondary NCT00972283
  • -1.2% vs -1.3% wk 32 · n 164 · Phase 4 · primary NCT02453685
  • -1.0% vs -1.1% wk 32 · n 195 · Phase 4 · primary NCT01165684
  • -0.5% vs 0% once weekly · wk 26 · n 40 · Phase 4 · primary NCT04538352
  • 4.1% vs 3.4% wk 26 · n 46 · Phase 4 · primary NCT01966978
  • -0.5% vs -0.5% n 115 · Phase 2 · primary NCT01194258
  • -0.8% vs -1.1% wk 21 · n 195 · Phase 4 · secondary NCT01165684
  • -0.5% vs -1% wk 10 · n 193 · Phase 4 · secondary NCT01165684
Insulin lispro (Lyumjev)
-0.4% vs -0.4%vs Insulin Lispro (Humalog)wk 26 · n 334NCT03214380
1 other result
  • -0.6% vs -0.6% wk 26 · n 388 · Phase 3 · primary NCT03952143

Body weight, change (kg)

insulin aspart
2.7 vs 2.2vs Insulin Glarginewk 26 · n 291NCT04880850
11 other results
  • 2.8 vs 2.2 BID · wk 26 · n 359 · Phase 3 · secondary NCT02762578
  • 2.8 vs 2 wk 26 · n 196 · Phase 3 · secondary NCT01513590
  • -1 vs 0.1 wk 26 · n 87 · Phase 3 · secondary NCT01388361
  • 0.7 vs 0.7 OD · wk 26 · n 147 · Phase 3 · secondary NCT01272193
  • 1.1 vs 1.4 BID · wk 26 · n 279 · Phase 3 · secondary NCT01059812
  • 0.9 vs 0.3 wk 16 · n 117 · Phase 3 · secondary NCT01474538
  • -8.6 vs 1.4 once weekly · wk 26 · n 40 · Phase 4 · secondary NCT04538352
  • -0.6 vs 3.1 wk 26 · n 46 · Phase 4 · secondary NCT01966978
  • 1.5 vs 1.6 n 115 · Phase 2 · secondary NCT01194258
  • 0.3 vs 0.8 wk 26 · n 22 · Phase 4 · secondary NCT00998335
  • 0.1 vs -0.1 wk 6 · n 33 · Phase 2 · secondary NCT00842361
Insulin lispro (Lyumjev)
—Not reported

HbA1c below 7%

insulin aspart
44% vs 20%vs Metformin, Insulin Detemir, Insulin Aspartwk 26 · n 46NCT01966978
Insulin lispro (Lyumjev)
—Not reported

Fasting plasma glucose, change

insulin aspart
-1.8 vs -1.6vs Insulin Glarginewk 26 · n 283NCT04880850
5 other results
  • -3.0 vs -1.6 BID · wk 26 · n 354 · Phase 3 · secondary NCT02762578
  • -4.4 vs -3.0 wk 26 · n 195 · Phase 3 · secondary NCT01513590
  • -0.1 vs -1.2 wk 26 · n 86 · Phase 3 · secondary NCT01388361
  • -2 vs -4.4 twice daily · wk 4.14 · n 115 · Phase 3 · secondary NCT02648217
  • 6.4 vs 4.9 wk 26 · n 22 · Phase 4 · secondary NCT00998335
Insulin lispro (Lyumjev)
—Not reported

3-point MACE (% with event)

insulin aspart
—Not posted · NCT01467323
Insulin lispro (Lyumjev)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety

Coverage. insulin aspart: 5 of 5 rows · Insulin lispro (Lyumjev): 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricinsulin aspart
Rows use multiple source trials
Insulin lispro (Lyumjev)
Rows use multiple source trials
HbA1c
absolute change · percentage points
No placebo or comparator arm
-1.45% (n=136) @ 26wka,b,c,d
NCT01680341 · Phase 3 · registry result, not featured evidence
show 1 more dose
-1.33% (n=136) @ 26wk
NCT01680341 · Phase 3 · registry result, not featured evidence
-0.44% (n=167) @ 12wkb,c,d
NCT04605991 · Phase 3 · combination · Type 2 Diabetes · phase 3
Dropout rate
0%once weeklye
NCT04538352 · Phase 4 · registry result, not featured evidence · combination
show 24 more results
22%
NCT01966978 · Phase 4 · registry result, not featured evidence · combination
11.3%
NCT02453685 · Phase 4 · registry result, not featured evidence
13.9%
NCT01165684 · Phase 4 · registry result, not featured evidence
—
NCT00998335 · Phase 4 · registry result, not featured evidence · combination
0%
NCT00591227 · Phase 4 · registry result, not featured evidence
5.5%
NCT04880850 · Phase 3 · registry result, not featured evidence
2.2%
NCT02906917 · Phase 3 · registry result, not featured evidence
4.2%BID
NCT02762578 · Phase 3 · registry result, not featured evidence
7.6%twice daily
NCT02648217 · Phase 3 · registry result, not featured evidence
15.4%IDegAsp Simple
NCT01680341 · Phase 3 · registry result, not featured evidence
12.5%IDegAsp Step Wise
NCT01680341 · Phase 3 · registry result, not featured evidence
—
NCT01474538 · Phase 3 · registry result, not featured evidence
5.1%
NCT01513590 · Phase 3 · registry result, not featured evidence
13.6%
NCT01388361 · Phase 3 · registry result, not featured evidence · combination
6.6%IDegAsp Simple
NCT01365507 · Phase 3 · registry result, not featured evidence
6.4%IDegAsp Step Wise
NCT01365507 · Phase 3 · registry result, not featured evidence
6.8%OD
NCT01272193 · Phase 3 · registry result, not featured evidence
13.1%BID
NCT01059812 · Phase 3 · registry result, not featured evidence
18.1%once daily
NCT00972283 · Phase 3 · registry result, not featured evidence
15.5%once daily
NCT01045447 · Phase 3 · registry result, not featured evidence
17.7%
NCT01045707 · Phase 3 · registry result, not featured evidence
12.1%
NCT01009580 · Phase 3 · registry result, not featured evidence
—
NCT01194258 · Phase 2 · registry result, not featured evidence
3%
NCT00842361 · Phase 2 · registry result, not featured evidence
—f
NCT03214380 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 16 more results
—
NCT03952143 · Phase 3 · combination · Type 2 Diabetes · phase 3
17.6%
NCT04605991 · Phase 3 · combination · Type 2 Diabetes · phase 3
—LY900014 After Meal
NCT03341312 · Phase 1 · registry result, not featured evidence
—LY900014 Before Meal
NCT03341312 · Phase 1 · registry result, not featured evidence
—15 U
NCT03286751 · Phase 1 · registry result, not featured evidence
—30 U
NCT03286751 · Phase 1 · registry result, not featured evidence
—7 U
NCT03286751 · Phase 1 · registry result, not featured evidence
—15 U
NCT03305822 · Phase 1 · registry result, not featured evidence
—15 U
NCT03232983 · Phase 1 · registry result, not featured evidence
—15 U
NCT03232983 · Phase 1 · registry result, not featured evidence
—15 U
NCT03232983 · Phase 1 · registry result, not featured evidence
—15 U
NCT03232983 · Phase 1 · registry result, not featured evidence
—LY900014 - Test (Part B)
NCT02703337 · Phase 1 · registry result, not featured evidence
—LY900014 - Test +15 Min (Part A)
NCT02703337 · Phase 1 · registry result, not featured evidence · combination
—LY900014 - Test -15 Min (Part A)
NCT02703337 · Phase 1 · registry result, not featured evidence
—LY900014 - Test 0 Min (Part A)
NCT02703337 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
—once weeklye
NCT04538352 · Phase 4 · registry result, not featured evidence · combination
show 24 more results
—
NCT01966978 · Phase 4 · registry result, not featured evidence · combination
0%
NCT02453685 · Phase 4 · registry result, not featured evidence
0.5%
NCT01165684 · Phase 4 · registry result, not featured evidence
—
NCT00998335 · Phase 4 · registry result, not featured evidence · combination
—
NCT00591227 · Phase 4 · registry result, not featured evidence
—
NCT04880850 · Phase 3 · registry result, not featured evidence
0.4%
NCT02906917 · Phase 3 · registry result, not featured evidence
0.3%BID
NCT02762578 · Phase 3 · registry result, not featured evidence
0%twice daily
NCT02648217 · Phase 3 · registry result, not featured evidence
2.2%IDegAsp Simple
NCT01680341 · Phase 3 · registry result, not featured evidence
1.5%IDegAsp Step Wise
NCT01680341 · Phase 3 · registry result, not featured evidence
—
NCT01474538 · Phase 3 · registry result, not featured evidence
1%
NCT01513590 · Phase 3 · registry result, not featured evidence
5.7%
NCT01388361 · Phase 3 · registry result, not featured evidence · combination
—IDegAsp Simple
NCT01365507 · Phase 3 · registry result, not featured evidence
—IDegAsp Step Wise
NCT01365507 · Phase 3 · registry result, not featured evidence
0.7%OD
NCT01272193 · Phase 3 · registry result, not featured evidence
3.2%BID
NCT01059812 · Phase 3 · registry result, not featured evidence
4.1%once daily
NCT00972283 · Phase 3 · registry result, not featured evidence
0%once daily
NCT01045447 · Phase 3 · registry result, not featured evidence
1.9%
NCT01045707 · Phase 3 · registry result, not featured evidence
1.8%
NCT01009580 · Phase 3 · registry result, not featured evidence
—
NCT01194258 · Phase 2 · registry result, not featured evidence
—
NCT00842361 · Phase 2 · registry result, not featured evidence
—f
NCT03214380 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 16 more results
—
NCT03952143 · Phase 3 · combination · Type 2 Diabetes · phase 3
2.7%
NCT04605991 · Phase 3 · combination · Type 2 Diabetes · phase 3
—LY900014 After Meal
NCT03341312 · Phase 1 · registry result, not featured evidence
—LY900014 Before Meal
NCT03341312 · Phase 1 · registry result, not featured evidence
—15 U
NCT03286751 · Phase 1 · registry result, not featured evidence
—30 U
NCT03286751 · Phase 1 · registry result, not featured evidence
—7 U
NCT03286751 · Phase 1 · registry result, not featured evidence
—15 U
NCT03305822 · Phase 1 · registry result, not featured evidence
—15 U
NCT03232983 · Phase 1 · registry result, not featured evidence
—15 U
NCT03232983 · Phase 1 · registry result, not featured evidence
—15 U
NCT03232983 · Phase 1 · registry result, not featured evidence
—15 U
NCT03232983 · Phase 1 · registry result, not featured evidence
—LY900014 - Test (Part B)
NCT02703337 · Phase 1 · registry result, not featured evidence
—LY900014 - Test +15 Min (Part A)
NCT02703337 · Phase 1 · registry result, not featured evidence · combination
—LY900014 - Test -15 Min (Part A)
NCT02703337 · Phase 1 · registry result, not featured evidence
—LY900014 - Test 0 Min (Part A)
NCT02703337 · Phase 1 · registry result, not featured evidence
Serious AEs
22.5%once weeklye
NCT04538352 · Phase 4 · registry result, not featured evidence · combination
show 24 more results
11.1%
NCT01966978 · Phase 4 · registry result, not featured evidence · combination
8.4%
NCT02453685 · Phase 4 · registry result, not featured evidence
9.1%
NCT01165684 · Phase 4 · registry result, not featured evidence
0%
NCT00998335 · Phase 4 · registry result, not featured evidence · combination
0%
NCT00591227 · Phase 4 · registry result, not featured evidence
7.6%
NCT04880850 · Phase 3 · registry result, not featured evidence
6.8%
NCT02906917 · Phase 3 · registry result, not featured evidence
4.4%BID
NCT02762578 · Phase 3 · registry result, not featured evidence
3.8%twice daily
NCT02648217 · Phase 3 · registry result, not featured evidence
5.2%IDegAsp Simple
NCT01680341 · Phase 3 · registry result, not featured evidence
7.5%IDegAsp Step Wise
NCT01680341 · Phase 3 · registry result, not featured evidence
11.8%
NCT01474538 · Phase 3 · registry result, not featured evidence
6.6%
NCT01513590 · Phase 3 · registry result, not featured evidence
4.6%
NCT01388361 · Phase 3 · registry result, not featured evidence · combination
0.7%IDegAsp Simple
NCT01365507 · Phase 3 · registry result, not featured evidence
4.3%IDegAsp Step Wise
NCT01365507 · Phase 3 · registry result, not featured evidence
3.4%OD
NCT01272193 · Phase 3 · registry result, not featured evidence
8.2%BID
NCT01059812 · Phase 3 · registry result, not featured evidence
18.5%once daily
NCT00972283 · Phase 3 · registry result, not featured evidence
4.3%once daily
NCT01045447 · Phase 3 · registry result, not featured evidence
11.3%
NCT01045707 · Phase 3 · registry result, not featured evidence
8.5%
NCT01009580 · Phase 3 · registry result, not featured evidence
6.5%
NCT01194258 · Phase 2 · registry result, not featured evidence
3%
NCT00842361 · Phase 2 · registry result, not featured evidence
7.7%f
NCT03214380 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 16 more results
8.4%
NCT03952143 · Phase 3 · combination · Type 2 Diabetes · phase 3
1.7%
NCT04605991 · Phase 3 · combination · Type 2 Diabetes · phase 3
0%LY900014 After Meal
NCT03341312 · Phase 1 · registry result, not featured evidence
0%LY900014 Before Meal
NCT03341312 · Phase 1 · registry result, not featured evidence
0%15 U
NCT03286751 · Phase 1 · registry result, not featured evidence
0%30 U
NCT03286751 · Phase 1 · registry result, not featured evidence
0%7 U
NCT03286751 · Phase 1 · registry result, not featured evidence
0%15 U
NCT03305822 · Phase 1 · registry result, not featured evidence
0%15 U
NCT03232983 · Phase 1 · registry result, not featured evidence
0%15 U
NCT03232983 · Phase 1 · registry result, not featured evidence
0%15 U
NCT03232983 · Phase 1 · registry result, not featured evidence
0%15 U
NCT03232983 · Phase 1 · registry result, not featured evidence
0%LY900014 - Test (Part B)
NCT02703337 · Phase 1 · registry result, not featured evidence
0%LY900014 - Test +15 Min (Part A)
NCT02703337 · Phase 1 · registry result, not featured evidence · combination
0%LY900014 - Test -15 Min (Part A)
NCT02703337 · Phase 1 · registry result, not featured evidence
0%LY900014 - Test 0 Min (Part A)
NCT02703337 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
once weeklye
pain 17.5%
upper respiratory infection 0%
NCT04538352 · Phase 4 · registry result, not featured evidence · combination
show 22 more results
gi 77.8%
headache 25.9%
other ae 7.4%
NCT01966978 · Phase 4 · registry result, not featured evidence · combination
nasopharyngitis 12.7%
headache 7.2%
arthralgia 6.6%
NCT02453685 · Phase 4 · registry result, not featured evidence
nasopharyngitis 8.1%
headache 5.1%
influenza 5.1%
NCT01165684 · Phase 4 · registry result, not featured evidence
covid-19 8.6%
diarrhoea 5.2%
diabetic retinopathy 4.1%
NCT04880850 · Phase 3 · registry result, not featured evidence
nasopharyngitis 13.6%
headache 10.2%
back pain 6%
NCT02906917 · Phase 3 · registry result, not featured evidence
BID
upper respiratory tract infection 21.1%
diabetic retinopathy 10%
viral upper respiratory tract infection 2.5%
NCT02762578 · Phase 3 · registry result, not featured evidence
twice daily
blood glucose decreased 35.4%
upper respiratory tract infection 6.2%
pyrexia 3.1%
NCT02648217 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 10.4%
nasopharyngitis 8.9%
headache 6.7%
NCT01680341 · Phase 3 · registry result, not featured evidence
nasopharyngitis 14.9%
influenza 9%
upper respiratory tract infection 7.5%
NCT01680341 · Phase 3 · registry result, not featured evidence
nasopharyngitis 4.2%
rhinitis allergic 4.2%
back pain 3.4%
NCT01474538 · Phase 3 · registry result, not featured evidence
nasopharyngitis 7.7%
NCT01513590 · Phase 3 · registry result, not featured evidence
nausea 20.7%
diarrhoea 10.3%
nasopharyngitis 10.3%
NCT01388361 · Phase 3 · registry result, not featured evidence · combination
upper respiratory tract infection 9%
nasopharyngitis 6%
NCT01365507 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 10.7%
nasopharyngitis 7.9%
NCT01365507 · Phase 3 · registry result, not featured evidence
OD
nasopharyngitis 22.4%
diabetic retinopathy 5.4%
NCT01272193 · Phase 3 · registry result, not featured evidence
BID
nasopharyngitis 18.3%
upper respiratory tract infection 7.5%
diabetic retinopathy 6.8%
NCT01059812 · Phase 3 · registry result, not featured evidence
once daily
nasopharyngitis 16.5%
upper respiratory tract infection 16.3%
headache 9.4%
NCT00972283 · Phase 3 · registry result, not featured evidence
once daily
headache 8.7%
nasopharyngitis 7.4%
diarrhoea 5.2%
NCT01045447 · Phase 3 · registry result, not featured evidence
nasopharyngitis 13.6%
hypertension 7.5%
back pain 6%
NCT01045707 · Phase 3 · registry result, not featured evidence
nasopharyngitis 11.6%
upper respiratory tract infection 7.6%
headache 5.8%
NCT01009580 · Phase 3 · registry result, not featured evidence
uterine leiomyoma 6.7%
arthralgia 6.5%
headache 6.5%
NCT01194258 · Phase 2 · registry result, not featured evidence
nasopharyngitis 9.1%
supraventricular extrasystoles 6.1%
NCT00842361 · Phase 2 · registry result, not featured evidence
f
nasopharyngitis 14%
upper respiratory tract infection 8%
diarrhoea 3.3%
NCT03214380 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 15 more results
upper respiratory tract infection 5.3%
NCT03952143 · Phase 3 · combination · Type 2 Diabetes · phase 3
injection site reaction 5.6%
NCT03341312 · Phase 1 · registry result, not featured evidence
injection site reaction 2.9%
NCT03341312 · Phase 1 · registry result, not featured evidence
15 U
headache 10%
nausea 5%
injection site reaction 2.5%
NCT03286751 · Phase 1 · registry result, not featured evidence
30 U
headache 14.6%
injection site reaction 14.6%
nausea 7.3%
NCT03286751 · Phase 1 · registry result, not featured evidence
7 U
headache 15%
injection site reaction 2.5%
nausea 2.5%
NCT03286751 · Phase 1 · registry result, not featured evidence
15 U
headache 5.3%
vessel puncture site thrombosis 5.3%
NCT03305822 · Phase 1 · registry result, not featured evidence
15 U
infusion site pain 12%
catheter site bruise 8%
vessel puncture site bruise 8%
NCT03232983 · Phase 1 · registry result, not featured evidence
15 U
injection site pain 11.5%
application site erythema 7.7%
catheter site bruise 7.7%
NCT03232983 · Phase 1 · registry result, not featured evidence
15 U
catheter site pain 10.7%
catheter site swelling 7.1%
application site erythema 3.6%
NCT03232983 · Phase 1 · registry result, not featured evidence
15 U
catheter site bruise 7.7%
infusion site erythema 7.7%
infusion site swelling 7.7%
NCT03232983 · Phase 1 · registry result, not featured evidence
headache 6.7%
back pain 0%
thrombophlebitis 0%
NCT02703337 · Phase 1 · registry result, not featured evidence
back pain 0%
headache 0%
thrombophlebitis 0%
NCT02703337 · Phase 1 · registry result, not featured evidence · combination
thrombophlebitis 6.9%
back pain 0%
headache 0%
NCT02703337 · Phase 1 · registry result, not featured evidence
thrombophlebitis 10.3%
back pain 0%
headache 0%
NCT02703337 · Phase 1 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dAssessment timepoints differ: 26 weeks versus 12 weeks.
  5. ePopulation comparability has not been reviewed for these studies.
  6. fPopulation comparability has not been reviewed for 14 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

insulin aspart

Weight -8.6 vs 1.4 Insulin kg @ 26wkonce weekly
absolute change · kg
NCT04538352 · Phase 4 · registry result, not featured evidence · combination
show 12 more results
-0.6 vs 3.1 Metformin, Insulin Detemir, Insulin Aspart kg @ 26wk
NCT01966978 · Phase 4 · registry result, not featured evidence · combination
NA vs -0.8 Insulin Detemir kg @ 13wk
NCT00998335 · Phase 4 · registry result, not featured evidence · combination
0.3 vs 0.8 Insulin Detemir kg @ 26wk
NCT00998335 · Phase 4 · registry result, not featured evidence · combination
2.73 vs 2.16 Insulin Glargine kg @ 26wk
NCT04880850 · Phase 3 · registry result, not featured evidence
2.82 vs 2.21 BIAsp 30 kg @ 26wkBID
NCT02762578 · Phase 3 · registry result, not featured evidence
0.89 vs 0.31 Insulin Lispro kg @ 16wk
NCT01474538 · Phase 3 · registry result, not featured evidence
2.8 vs 2 BIAsp 30 kg @ 26wk
NCT01513590 · Phase 3 · registry result, not featured evidence
-1 vs 0.1 IDeg kg @ 26wk
NCT01388361 · Phase 3 · registry result, not featured evidence · combination
0.7 vs 0.7 IGlar kg @ 26wkOD
NCT01272193 · Phase 3 · registry result, not featured evidence
1.1 vs 1.4 BIAsp 30 kg @ 26wkBID
NCT01059812 · Phase 3 · registry result, not featured evidence
1.5 vs 1.6 Insulin-lispro kg*
NCT01194258 · Phase 2 · registry result, not featured evidence · converted to kg from 3.35 pounds as posted
0.09 vs -0.1 Mix30 kg @ 6wk
NCT00842361 · Phase 2 · registry result, not featured evidence
HbA1c -0.5 vs 0 Insulin actual mean A1C change @ 26wkonce weekly
absolute change · actual mean A1C change
NCT04538352 · Phase 4 · registry result, not featured evidence · combination
HbA1c Less Than 7% 44% (n=46) vs 20% (n=44) Metformin, Insulin Detemir, Insulin Aspart @ 26wk
responder rate · % of participants
NCT01966978 · Phase 4 · registry result, not featured evidence · combination
Treatment Failure 7.4% (n=46) vs 16.1% (n=44) Metformin, Insulin Detemir, Insulin Aspart @ 13wk
responder rate · % of participants
NCT01966978 · Phase 4 · registry result, not featured evidence · combination
HbA1c Less Than 7 Without Severe Hypoglycemia 42.3% (n=168) vs 56.3% (n=167) insulin glargine + insulin aspart @ 32wk
responder rate · % of participants
NCT02453685 · Phase 4 · registry result, not featured evidence
HbA1c Less Than 7 19.2% (n=193) vs 56.3% (n=183) insulin aspart @ 10wk
absolute value · percentage points
NCT01165684 · Phase 4 · registry result, not featured evidence
show 2 more results
45.1% (n=195) vs 65.4% (n=188) insulin aspart @ 21wk
NCT01165684 · Phase 4 · registry result, not featured evidence
55.9% (n=195) vs 63.3% (n=188) insulin aspart @ 32wk
NCT01165684 · Phase 4 · registry result, not featured evidence
Fasting Plasma Glucose 7.1 vs 6.7 insulin aspart mmol/L @ 10wk
absolute value · mmol/L
NCT01165684 · Phase 4 · registry result, not featured evidence
show 2 more results
7.1 vs 7 insulin aspart mmol/L @ 21wk
NCT01165684 · Phase 4 · registry result, not featured evidence
7.12 vs 7.01 insulin aspart mmol/L @ 32wk
NCT01165684 · Phase 4 · registry result, not featured evidence
Postprandial Glucose Increment 2.3 vs 1.4 insulin aspart mmol/L @ 10wk
absolute value · mmol/L
NCT01165684 · Phase 4 · registry result, not featured evidence
show 2 more results
1.9 vs 1.5 insulin aspart mmol/L @ 21wk
NCT01165684 · Phase 4 · registry result, not featured evidence
1.64 vs 1.28 insulin aspart mmol/L @ 32wk
NCT01165684 · Phase 4 · registry result, not featured evidence
Body Weight 89.32 vs 89.8 insulin aspart kg @ 32wk
absolute value · kg
NCT01165684 · Phase 4 · registry result, not featured evidence
BMI 31.86 vs 32.03 insulin aspart kg @ 32wk
absolute value · kg
NCT01165684 · Phase 4 · registry result, not featured evidence
Hepatic Fat Fraction NA vs 6.7% (n=30) Insulin Detemir @ 13wk
percent change · % of baseline
NCT00998335 · Phase 4 · registry result, not featured evidence · combination
show 1 more result
5.9% (n=22) vs 8.4% (n=30) Insulin Detemir @ 26wk
NCT00998335 · Phase 4 · registry result, not featured evidence · combination
HbA1c NA vs 7.4% (n=30) Insulin Detemir @ 13wk
absolute value · percentage points
NCT00998335 · Phase 4 · registry result, not featured evidence · combination
show 2 more results
6.7% (n=22) vs 6.9% (n=30) Insulin Detemir @ 26wk
NCT00998335 · Phase 4 · registry result, not featured evidence · combination
7.4% (n=111) vs 7.5% (n=112) Insulin Lispro @ 16wk
NCT01474538 · Phase 3 · registry result, not featured evidence

+ 43 further endpoints in the CSV export.

Insulin lispro (Lyumjev)

HbA1c 7.0 or Less 58.2% (n=316) vs 52.5% (n=320) Insulin Lispro (Humalog) @ 26wk
event count · % of participants
NCT03214380 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 184 Participants as posted
PPG 1H Excursion mg/dL 86.2 vs 100.8 Insulin Lispro (Humalog) mg @ 26wk
absolute value · mg
NCT03952143 · Phase 3 · combination · Type 2 Diabetes · phase 3
PPG 2 h Excursion mg/dL 6.18 vs 7.39 Insulin Lispro (Humalog) mmol/L @ 26wk
absolute value · mmol/L
NCT03952143 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from 111.4 mg/dL as posted
HbA1c Less Than 7% 46.65% (n=358) vs 44.5% (n=191) Insulin Lispro (Humalog) @ 26wk
responder rate · % of participants
HbA1c < 7%
NCT03952143 · Phase 3 · combination · Type 2 Diabetes · phase 3
HbA1c 6 5 or Less 27.93% (n=358) vs 27.23% (n=191) Insulin Lispro (Humalog) @ 26wk
responder rate · % of participants
HbA1c ≤ 6.5%
NCT03952143 · Phase 3 · combination · Type 2 Diabetes · phase 3
Time in Range Daytime 3.8 % of time @ 12wk
absolute change · % of time
No placebo or comparator arm
NCT04605991 · Phase 3 · combination · Type 2 Diabetes · phase 3
Time in Range 24 h 3.3 % of time @ 12wk
absolute change · % of time
No placebo or comparator arm
NCT04605991 · Phase 3 · combination · Type 2 Diabetes · phase 3
Time Below 54 0 % of time @ 12wk
absolute change · % of time
No placebo or comparator arm
24-hour Period
NCT04605991 · Phase 3 · combination · Type 2 Diabetes · phase 3
Time Above 180 -3.4 % of time @ 12wk
absolute change · % of time
No placebo or comparator arm
24-Hour Period
NCT04605991 · Phase 3 · combination · Type 2 Diabetes · phase 3
Time Above 2.50 -1.07 % of time @ 12wk
absolute change · % of time
No placebo or comparator arm
24-Hour Period
NCT04605991 · Phase 3 · combination · Type 2 Diabetes · phase 3
Postprandial iAUC 0 1H -2.46 mg @ 12wk
absolute change · mg
No placebo or comparator arm
Overall - across meals
NCT04605991 · Phase 3 · combination · Type 2 Diabetes · phase 3
Postprandial iAUC 0-2h -8.8 mg @ 12wk
absolute change · mg
No placebo or comparator arm
Overall - across meals
NCT04605991 · Phase 3 · combination · Type 2 Diabetes · phase 3

+ 6 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: insulin aspart's landscape · Insulin lispro (Lyumjev)'s landscape